Newton Biocapital

Newton Biocapital is a Brussels-based venture capital firm with a strong presence in both Europe and Japan, focusing exclusively on the life sciences sector. Established in 2017, the firm’s investment strategy is centered on supporting companies that tackle chronic diseases, with an emphasis on oncology, metabolic diseases, and neurological conditions. Newton Biocapital plays a hands-on role in its portfolio companies, often leading funding rounds and taking board positions to guide scientific and clinical strategies​. The firm manages two funds—Newton Biocapital I (€114M) and Newton Biocapital II, which is currently targeting €150M. NBC I invested in 14 companies across Europe and Japan, including university spin-offs like Epics Therapeutics and ChromaCure in Belgium, and biotech firms like EditForce in Japan. Newton's approach is deeply integrated with the local ecosystems in both regions, leveraging their strong ties to academic institutions, industry experts, and international investors to facilitate cross-border growth and exits​. Newton’s team combines scientific, regulatory, and investment expertise, led by CEO Alain Parthoens. With offices in Brussels and Tokyo, they are uniquely positioned to bridge the innovation pipeline between Europe and Japan, driving impactful advancements in life sciences​.